Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy

AIDS

Volumn 14, Issue 7, 2000, Pages 821-826

  O'Brien, Thomas R ^a   McDermott, David H ^b   Ioannidis, John P A ^c   Carrington, Mary ^d   Murphy, Philip M ^b   Havlir, Diane V ^e   Richman, Douglas D ^e,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF IOANNINA   (Greece)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

AIDS; Antiretroviral therapy; CC chemokine receptor 5; Genotype; HIV; HIV RNA; Protease inhibitors; Treatment response

Indexed keywords

ANTIRETROVIRUS AGENT; BETA CHEMOKINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; INDINAVIR; LAMIVUDINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ALLELE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TREATMENT FAILURE;

ADULT; ALLELES; ANTI-HIV AGENTS; CHEMOKINES, CXC; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0034122740     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005050-00008     Document Type: Article

References (24)

1. 1. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
2. 2. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
3. 3. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
4. 4. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997, 3:23-36.
5. 5. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32 [letter]. Lancet 1997, 349:4-1219.
6. 6. Ioannidis JP, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DC, Goedert JJ. Genetic effects on HIV disease progression [letter]. Nat Med 1998, 4:536.
7. 7. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997, 277:959-965.
8. 8. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998, 352:866-870.
9. 9. Martin MP, Dean M., Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911.
10. 10. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rate of HIV-1 disease progression. Nat Med 1998, 4:786-793.
11. 11. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998, 279:389-393.
12. 12. Meyer L., Magierowska H, Hubert J-B, et al. CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. AIDS 1999, 13:624-625.
13. 13. O'Brien TR., Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-110.
14. 14. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by quantity of virus in plasma. Science 1996, 272:1167-1170.
15. 15. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998, 339:1261-8.
16. 16. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1997, 41:284-291.
17. 17. Kalbfleisch J, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 1980.
18. 18. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley; 1989.
19. 19. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 1997, 185:1681-1691.
20. 20. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999, 163:4597-4603.
21. 21. Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
22. 22. Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA. Association of the CCR5 Δ32 mutation with improved response to anitretroviral therapy [letter]. JAMA 1999, 282:734.
23. 23. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283(5408):1748-1752.
24. 24. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.